Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMBRIA-2: camizestrant versus standard adjuvant endocrine therapy in ER-positive/HER2-negative early breast cancer
jRCT2061230074Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Standard-of-care endocrine therapy ± abemaciclib with Camizestrant ± abemaciclib (2 arms). Primary endpoint: Invasive breast cancer-free survival. Started Mar 2024; status: active, not recruiting.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2061230074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230074.